PEGylation Partnership

A strategic alliance focused on the processing of biological drugs to increase half-life and reduce production costs.
QuiaPEG Pharmaceuticals AB, an emerging biotechnology company with a cutting-edge PEGylation technology platform, joins Cobra in a strategic alliance focused on the processing of biological drugs for half-life extension (HLE) and to reduce production costs.

Cobra provides a ‘one-stop-shop’ service offering to meet customers’ PEGylation needs; combining the advantages it has as an experienced and trusted CDMO with the technical expertise at QuiaPEG.
PEGylation is proven to be a reliable method for improving the pharmacokinetic profile of drugs and customers will have access to a unique technology platform for early drug development, life-cycle management, and the improvement of existing drugs, so called biobetters.

Find out more: Cobra Biologics and QuiaPEG Announce Strategic Collaboration Offering a Novel PEGylation Technology Platform

More about Superior PEGylation Platform (in partnership with QuiaPEG)...

In order to provide complete functionality, this web site needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site. It is recommended that you allow all cookies. Allow all cookies